
Chemical and Pharmaceutical Bulletin p. 1130 - 1134 (1998)
Update date:2022-08-03
Topics:
Baba, Atsuo
Makino, Haruhiko
Ohta, Yoshikazu
Sohda, Takashi
The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (1, TAK-603), which is under clinical evaluation as a new type of disease-modifying antirheumatic drug (DMARD), were prepared to confirm th
View MoreWuhan Chemwish Technology Co., Ltd
website:http://www.chemwish.com/
Contact:+86-27-67849912
Address:Room 1311, Unit 2, Block1, Innovation Road East Lake High-tech Development Zone Wuhan, Hubei,P.R. China
Shanghai Maxchemco Chemical Industry Co., Ltd.
Contact:(86)21-51079223
Address:No.1305-8, B241, the Ecust Park, Huajing Road, Xuhui District, Shanghai
QINGDAO DEVELOP chemistry Co.,Limited
Contact:+86-532-85807910
Address:98#Nanjing Road, Qingdao, China 266071
GUANGZHOU MEDCAN PHARMATECH LTD
website:http://www.gzmedcan.com
Contact:+86-20-82519649
Address:Building J,Room 101,1 JiangtashanRd,Guang Zhou Science City,Guang Zhou ,China
Shijiazhuang City Xiehe Pharmaceutical Co., Ltd
Contact:+86-311-80817929
Address:Shangzhuang,Shijiazhuang,China
Doi:10.1039/c6cc05707a
(2016)Doi:10.1039/a802797h
(1998)Doi:10.1039/a801922c
(1998)Doi:10.1021/jo01046a525
(1963)Doi:10.1016/j.jfluchem.2005.03.020
(2005)Doi:10.1055/s-2006-950244
(2006)